| Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for patients suffering from rare diseases using its cell penetrating peptide technology platform. Co.'s lead product candidate, CTI-1601, is a biologic fusion protein that is administered subcutaneously, consists of a cell penetrating peptide (CPP) genetically fused to human frataxin (FXN), and includes a mitochondrial targeting sequence. Using its proprietary peptide delivery technology, CTI-1601 carries the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off to yield mature FXN. The LRMR average annual return since 2014 is shown above.
The Average Annual Return on the LRMR average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LRMR average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LRMR average annual return calculation with any dividends reinvested as applicable (on ex-dates).